Literature DB >> 35464263

Immunotherapy for hepatocellular carcinoma: a "CRAFITY" approach to patient stratification.

Salim I Khakoo1.   

Abstract

Entities:  

Year:  2022        PMID: 35464263      PMCID: PMC9023814          DOI: 10.21037/hbsn-2021-32

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  8 in total

1.  Metabolic reprogramming of natural killer cells in obesity limits antitumor responses.

Authors:  Xavier Michelet; Lydia Dyck; Andrew Hogan; Roisin M Loftus; Danielle Duquette; Kevin Wei; Semir Beyaz; Ali Tavakkoli; Cathriona Foley; Raymond Donnelly; Cliona O'Farrelly; Mathilde Raverdeau; Ashley Vernon; William Pettee; Donal O'Shea; Barbara S Nikolajczyk; Kingston H G Mills; Michael B Brenner; David Finlay; Lydia Lynch
Journal:  Nat Immunol       Date:  2018-11-12       Impact factor: 25.606

2.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

Review 3.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

4.  Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

Authors:  Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Vera Himmelsbach; Kornelius Schulze; Johann von Felden; Thorben W Fründt; Marc Stadler; Harald Heinzl; Kateryna Shmanko; Stephan Spahn; Pompilia Radu; Alexander R Siebenhüner; Joachim C Mertens; Nuh N Rahbari; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias P Ebert; Andreas Teufel; Sara De Dosso; David J Pinato; Tiziana Pressiani; Tobias Meischl; Lorenz Balcar; Christian Müller; Mattias Mandorfer; Thomas Reiberger; Michael Trauner; Nicola Personeni; Lorenza Rimassa; Michael Bitzer; Jörg Trojan; Arndt Weinmann; Henning Wege; Jean-François Dufour; Markus Peck-Radosavljevic; Arndt Vogel; Matthias Pinter
Journal:  J Hepatol       Date:  2021-10-12       Impact factor: 30.083

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 6.  Advances in molecular classification and precision oncology in hepatocellular carcinoma.

Authors:  Sandra Rebouissou; Jean-Charles Nault
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

Review 7.  Advances in immunotherapy for hepatocellular carcinoma.

Authors:  Bruno Sangro; Pablo Sarobe; Sandra Hervás-Stubbs; Ignacio Melero
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-04-13       Impact factor: 73.082

8.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Authors:  Dominik Pfister; Nicolás Gonzalo Núñez; Roser Pinyol; Olivier Govaere; Matthias Pinter; Marta Szydlowska; Revant Gupta; Mengjie Qiu; Aleksandra Deczkowska; Assaf Weiner; Florian Müller; Ankit Sinha; Ekaterina Friebel; Thomas Engleitner; Daniela Lenggenhager; Anja Moncsek; Danijela Heide; Kristin Stirm; Jan Kosla; Eleni Kotsiliti; Valentina Leone; Michael Dudek; Suhail Yousuf; Donato Inverso; Indrabahadur Singh; Ana Teijeiro; Florian Castet; Carla Montironi; Philipp K Haber; Dina Tiniakos; Pierre Bedossa; Simon Cockell; Ramy Younes; Michele Vacca; Fabio Marra; Jörn M Schattenberg; Michael Allison; Elisabetta Bugianesi; Vlad Ratziu; Tiziana Pressiani; Antonio D'Alessio; Nicola Personeni; Lorenza Rimassa; Ann K Daly; Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Arndt Vogel; Markus Peck-Radosavljevic; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Jörg Trojan; Kornelius Schulze; Henning Wege; Sandra Koch; Arndt Weinmann; Marco Bueter; Fabian Rössler; Alexander Siebenhüner; Sara De Dosso; Jan-Philipp Mallm; Viktor Umansky; Manfred Jugold; Tom Luedde; Andrea Schietinger; Peter Schirmacher; Brinda Emu; Hellmut G Augustin; Adrian Billeter; Beat Müller-Stich; Hiroto Kikuchi; Dan G Duda; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias Philip Ebert; Nuh Rahbari; Henrik E Mei; Axel Ronald Schulz; Marc Ringelhan; Nisar Malek; Stephan Spahn; Michael Bitzer; Marina Ruiz de Galarreta; Amaia Lujambio; Jean-Francois Dufour; Thomas U Marron; Ahmed Kaseb; Masatoshi Kudo; Yi-Hsiang Huang; Nabil Djouder; Katharina Wolter; Lars Zender; Parice N Marche; Thomas Decaens; David J Pinato; Roland Rad; Joachim C Mertens; Achim Weber; Kristian Unger; Felix Meissner; Susanne Roth; Zuzana Macek Jilkova; Manfred Claassen; Quentin M Anstee; Ido Amit; Percy Knolle; Burkhard Becher; Josep M Llovet; Mathias Heikenwalder
Journal:  Nature       Date:  2021-03-24       Impact factor: 49.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.